BREAKING NEWS
Source: Medical News -NSAIDs-Heart Failure  Sep 07, 2022  19 days ago
BREAKING! Danish Study Shows That Common NSAIDs Like Ibuprofen and Diclofenac Linked To Increased Risk Of Heart Failure In Diabetics!
503 Shares
facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
BREAKING! Danish Study Shows That Common NSAIDs Like Ibuprofen and Diclofenac Linked To Increased Risk Of Heart Failure In Diabetics!
Source: Medical News -NSAIDs-Heart Failure  Sep 07, 2022  19 days ago
A new study by Danish researchers the Copenhagen University Hospital in Denmark has found that the usages of common NSAIDs (non-steroidal anti-inflammatory drugs) like Ibuprofen and Diclofenac by diabetics were linked to a higher risk of heart failure.


 
The study findings were presented during the recent European Society of Cardiology annual congress or ESC Congress 2022 and will be published shortly.
https://www.escardio.org/Congresses-&-Events/ESC-Congress
 
The study said that the short-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is linked to a first-time hospitalization for heart failure in individuals with type 2 diabetes.
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most common form of anti-inflammatory medication. 
 
In most countries, many are available as over the counter drugs that do not need a doctor’s prescription. However, in countries like Denmark and most parts of Europe, a prescription is needed.
 
The most popular NSAIDs include ibuprofen (often known as Advil), diclofenac (goes under the brand name Voltaren), celecoxib (brand name Celebrex) and naproxen (known by the brand name Aleve and Naprosyn).
 
Unknown to many, despite their widespread use, these drugs can have side effects.
 
First author of the study Dr Anders Holt of Copenhagen University Hospital told Thailand Medical News, “In our research, approximately one in six patients with type 2 diabetes claimed at least one NSAID prescription within one year. In general, we always recommend that patients consult their doctor before starting a new medication, and with results from this study, we hope to help doctors mitigate risk if prescribing NSAIDs.”
 
Past studies have already showed that in the general population, NSAID usage is linked to an increased risk of heart failure.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422108/
 
https://journals.lww.com/ebp/Citation/2019/10000/Do_NSAIDs_increase_the_risk_of_congestive_heart.1.aspx
 
https://www.bmj.com/content/354/bmj.i4857
 
https://www.health.harvard.edu/blog/nsaids-how-dangerous-are-they-for-your-heart-2019010715677
 
However, data are lacking for patients with type 2 diabetes.  NSAIDs may be significantly more harmful in individuals with type 2 diabetes since they are more likely to experience heart failure than those without the condition.
 
The study looked at the relationship between short-term NSAID usage and the incidence of first-time heart failure hospitalization in a nationwide cohort of type 2 diabetes patients.
 
The study team ana lyzed Danish registries to identify individuals with type 2 diabetes diagnosed between 1998 and 2021. Patients with heart failure or a rheumatological condition that necessitated long-term NSAID treatment were not eligible.
 
Importantly, prior to the first heart failure hospitalization, information on prescriptions for oral NSAIDs (celecoxib, diclofenac, ibuprofen, and naproxen) was gathered.
 
The study team analyzed the links between short-term NSAID usage and the likelihood of first-time heart failure hospitalization utilizing a case-crossover approach in which each patient served as his or her own control.
 
The research included 331,189 patients with type 2 diabetes. The average age was 62 years and 44% were women.
 
In the study, during the first year after inclusion in the study, 16% of patients claimed at least one NSAID prescription while 3% claimed at least three prescriptions. Ibuprofen was used by 12.2% of patients, diclofenac by 3.3%, naproxen by 0.9%, and celecoxib by 0.4%.
 
The study findings showed that during a median follow-up of 5.85 years, 23,308 patients were hospitalized with heart failure for the first time.
 
The study findings showed that NSAID use was associated with an elevated risk of first-time heart failure hospitalization, with an odds ratio (OR) of 1.43 (95% confidence interval [CI] 1.27–1.63).
 
Interestingly, when individual NSAIDs were analyzed separately, the risk of heart failure hospitalization was increased following the use of diclofenac or ibuprofen, with corresponding ORs of 1.48 (95% CI 1.10–2.00) and 1.46 (95% CI 1.26–1.69), respectively.
 
However, the findings showed that celecoxib and naproxen were not associated with an increased risk, potentially due to the small proportion of claimed prescriptions.
 
The study team also analyzed the risk of heart failure with NSAID use in subgroups of patients. No association was found in patients with normal glycated hemoglobin (HbA1c) levels (below 48 mmol/mol), which indicates well-controlled diabetes.
 
However, strong associations were found in patients above 65 years of age, while no association was found in those below 65 years of age. The strongest association was found in very infrequent or new users of NSAIDs.
 
The study team noted that data on over-the-counter use of NSAIDs were not included in the study.
 
The study team noted that “this was a limitation but likely had no impact on the results since a previous report found that over-the-counter NSAIDs comprise a small proportion of total use.”
 
The study team however noted that this was an observational study and hence it cannot be totally concluded that NSAIDs cause heart failure in patients with type 2 diabetes. However, the results suggest that a potential increased risk of heart failure should be taken into account when considering the use of these medications.
 
The study team also said that on the contrary, the study data indicate that it may be safe to prescribe short-term NSAIDs for patients below 65 years of age and those with well-controlled diabetes.
 
The study was funded by the Danish Heart Foundation.
 
For the latest Drug News, keep on logging to Thailand Medical News.

MOST READ

Aug 13, 2020  2 years ago
Source: Supplements For COVID-19
Feb 05, 2020  3 years ago
Source : Thailand Medical news